311
Editorial Introduction
Editorial: The Future of Cardiac Electrophysiology Review
Kelley P. Anderson
312-314
Selection of Pacing Mode after Interruption of Atrioventricular Conduction for Atrial Fibrillation: Observations from the PA3 Clinical Trial
Anne M. Gillis
315-324
Comparison of Permanent Left Ventricular and Biventricular Pacing in Patients with Heart Failure and Chronic Atrial Fibrillation: A Prospective Hemodynamic Study
Stephane Garrigue, Pierre Bordachar, Sylvain Reuter, Pierre Jaïs and Michel Haïssaguerre, et al.
325-328
Is Bachmann's Bundle the Only Right Site for Single-Site Pacing to Prevent Atrial Fibrillation? Results of a Multicenter Randomized Trial
Steven J. Bailin
329-332
Multisite Atrial Pacing for Atrial Fibrillation Prevention: Where to Go from Here?
AnandRamdat Misier, Willem P. Beukema and Roger Willems
333-340
Detection of Atrial Fibrillation by Permanent Pacemakers: Observations from the STOP AF Trial
C.J. Plummer and J.M. McComb
341-344
Effectiveness of Rapid Atrial Pacing for Termination of Drug Refractory Atrial Fibrillation: Results of a Dual Chamber Implantable Cardioverter Defibrillator Trial
Michael R. Gold, Robert B. Leman and David E. Euler
345-347
Atrial Pacing Therapies for Prevention of Atrial Fibrillation in Patients with Implantable Defibrillators
Anne M. Gillis
348-351
Efficacy of Atrial Antitachycardia Functions for Treating Atrial Fibrillation: Observations in Patients with a Dual-Chamber Defibrillator
Renato Ricci, Carlo Pignalberi and Massimo Santini
352-354
Does Rapid Atrial Pacing Terminate Atrial Fibrillation? A Comparison of Laboratory and Device Termination Studies
Andrew R. J. Mitchell and Neil Sulke
355-358
Atrial Arrhythmia Burden as an Endpoint in Clinical Trials: Is it the Best Surrogate? Lessons from a Multicenter Defibrillator Trial
David E. Euler and Paul A. Friedman
359-365
Does Sinus Rhythm Beget Sinus Rhythm? Effects of Prompt Cardioversion on the Frequency and Persistence of Recurrent Atrial Fibrillation
Hung-Fat Tse and Chu-Pak Lau
366-369
AFFIRM and RACE Trials: Implications for the Management of Atrial Fibrillation
Joseph L. Blackshear and Robert E. Safford
370-371
Atrial Fibrillation: Should we Target Platelets or the Coagulation Pathway?
Kiat T. Tan and Gregory Y. H. Lip
372-373
Aspirin—Anticoagulant Combination in Patients with Non Valvular Atrial Fibrillation Commentary on the FFAACS Study Results
Philippe P. Lechat
374-378
Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in
Carl van Walraven, Robert G. Hart, Daniel E. Singer, Peter J. Koudstaal and Stuart Connolly
379-381
Do Anticoagulation Management Services Improve Care? Implications of the Managing Anticoagulation Services Trial
David B. Matchar
382-386
Use of Subcutaneous Enoxaparin Compared to Intravenous Heparin and Oral Phenprocoumon in the Setting of Cardioversion—The ACE Study (Anticoagulation in Cardioversion Using Enoxaparin)
Christoph Stellbrink, Uwe Nixdorff, Thomas Hofmann, Walter Lehmacher and WernerGünther Daniel, et al.
387-391
Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation: ACUTE Trial Update
Craig R. Asher and Allan L. Klein
392-396
Cardioversion Related Thromboembolism: Value of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
Karlheinz Seidl and Jochen Senges
397-400
Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future
Michael H. Kim, Richard G. Trohman and Kim A. Eagle
401-405
Relationships between Pacing Mode and Quality of Life: Evidence from Randomized Clinical Trials
David Newman
406-410
Selecting the Appropriate Pacing Mode for Patients with Sick Sinus Syndrome: Evidence from Randomized Clinical Trials
A.E. Albertsen and J.C. Nielsen
411-415
Second Vasovagal Pacemaker Study (VPS II): Rationale, Design, Results, and Implications for Practice and Future Clinical Trials
Robert Sheldon and Stuart Connolly
416-420
Pacing for Vasovagal Syncope After the Second Vasovagal Pacemaker Study (VPS II): A Matter of Judgement
Geoffrey M. Trim, Andrew D. Krahn, George J. Klein, Allan C. Skanes and Raymond Yee
421-429
Cardiac Resynchronization Therapy with or without an Implantable Defibrillator: Only Indicated When Everything Else has Failed?
J. Ghosh, Gerry Kaye and J.G.F. Cleland
430-433
MADIT-II: Substudies and Their Implications
Arthur J. Moss
434-437
Risk Stratification for Sudden Death: Do We Need Anything More Than Ejection Fraction?
Alfred E. Buxton
438-442
Enhancing Specificity Without Sacrificing Sensitivity: Potential Benefits of Using Microvolt T-Wave Alternans Testing to Risk Stratify the MADIT-II Population
Richard J. Cohen
443-446
Using the MADIT II Criteria for Implantable Cardioverter Defibrillators—What is the Role of the Food and Drug Administration Approval?
Helen S. Barold
447-451
The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims
Gerian Grönefeld, Stuart J. Connolly and Stefan H. Hohnloser
452-456
Amiodarone versus Implantable Defibrillator (AMIOVIRT): Background, Rationale, Design, Methods, Results and Implications
Mevan Wijetunga and S.Adam Strickberger
457-462
DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)
Andi Schaechter and Alan H. Kadish
463-467
Clinical Trials of Prophylactic Implantable Defibrillator Therapy in Patients with Nonischemic Cardiomyopathy: What have We Learned and What can We Expect from Future Trials?
Wolfram Grimm
468-472
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: Rationale, Design, Results, Clinical Implications and Lessons for Future Trials
Bruce L. Wilkoff and the DAVID Trial Investigators
473-478
Clinical Significance of Device-Related Complications in Clinical Trials and Implications for Future Trials: Insights from the Antiarrhytmics versus Implantable Defibrillators (AVID) Trial
Jack Kron
479-482
Cost-Effectiveness of the Implantable Cardioverter Defibrillator
Mark A. Hlatky, Gillian D. Sanders and Douglas K. Owens